Yantai Lannacheng Biotech Co., Ltd. was established in early 2021, with its headquarters in Yantai, China, and a subsidiary in Singapore. Founded by Dongcheng Pharmaceutical Group, a leading enterprise with significant influence in China’s nuclear medicine sector, Lannacheng is dedicated to the research, development, and registration of first-in-class innovative radiopharmaceuticals integrating diagnosis and therapy. The company is developing various theranostic radiopharmaceutical pipelines with strong translational potential, serving as a core part of Dongcheng’s nuclear medicine ecosystem.

Lannacheng has established a pipeline comprising 13 drug candidates, including seven diagnostic radiopharmaceuticals and six therapeutic radiopharmaceuticals. The company’s R&D engine integrates key capabilities such as target validation, radioisotope selection, and linker design, and is further strengthened by its proprietary pharmacokinetic optimization technologies and dual-target drug development platform. In parallel, the company has commenced construction of a new manufacturing facility in Yantai, Shandong Province, covering approximately 4,886 square meters. The facility is designed in compliance with stringent cGMP standards and is expected to be completed by the first quarter of 2026. This initiative aims to enhance the company’s end-to-end operational capabilities from manufacturing to commercialization and establish a closed-loop system for radiopharmaceutical R&D and industrialization.

Starting at the microscopic level and advancing to the clinic, Lannacheng harnesses innovation to make precision medicine accessible to more patients, with a broad pipeline covering PSMA, FAP, integrin αvβ3, and multiple novel early-stage targets. This approach has produced a diverse, well-structured product portfolio.

Lannacheng regards intellectual property as the cornerstone of innovation and a strategic foundation for global competitiveness. The company has systematically established a global intellectual property portfolio covering its core technologies and entire product pipeline. It has also proactively implemented forward-looking patent strategies in key jurisdictions, including China, the United States, Australia, Canada, Japan, South Korea, and Singapore, to ensure that its core innovations are comprehensively protected worldwide. This robust IP framework provides a solid foundation for the rapid advancement of the pipeline, the secure execution of technical collaborations, and future global commercialization, effectively enabling the translation of innovative value from the laboratory to the broader market.

Powered by cutting-edge innovation and a strategy centered on multi-target approaches, diverse radionuclides, and integrated theranostics, Lannacheng is advancing nuclear medicine from diagnostic imaging to personalized precision therapy. The company aims to build a globally competitive radiopharmaceutical enterprise, establishing new paradigms for solid tumor treatment through precision theranostic systems and ensuring rapid translation of radiopharmaceuticals into clinical practice to benefit patients worldwide.